Biology, Pathophysiology and Pharmacotherapy for Schizophrenia
A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Physiology and Pathology".
Deadline for manuscript submissions: closed (29 March 2024) | Viewed by 180
Special Issue Editors
Interests: psycho- and neuropharmacology
Interests: cancer and anticancer peptides; substance P/neurokinin-1 receptor system; neurokinin-1 receptor antagonists
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Schizophrenia and schizoaffective disorder are disabling mental diseases, which can possibly remanifest as a recurrent psychosis. Therefore, treatment with antipsychotic drugs is essential. Adverse effects, such as movement disturbances as well as metabolic and cardiac adverse effects reduce patients’ adherence to medical treatment. In recent years, new antipsychotic drugs, which interact with new specific receptors, have been found and admitted for the treatment of this disease. Have these new antipsychotic drugs made progress in the treatment of schizophrenic symptoms, have they caused less adverse effects, and have they had a secure therapeutic effect? Has patients’ adherence become more reliable and have schizophrenic symptoms been treated better? Have therapeutic measures beside pharmacological treatment made progress in medical treatment? Clinical trials and case reports show the development of the successful treatment of disease symptoms.
Prof. Dr. Felix Martin Werner
Prof. Dr. Rafael Coveñas Rodríguez
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- antipsychotic drug
- schizophrenia
- schizoaffective disorder
